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INTRODUCTION: 
The human body is defined by many complex and inconsistent characteristics. For 
example, the body forms blood clots in traumatic events, but blood clots are likewise 
associated with hazardous or fatal conditions. Platelets are small cells, derived from the 
precursor megakaryocytes, which are responsible for blood clotting to prevent bleeding from 
a ruptured blood vessel. Platelets fasten to each other and release a coagulation factor that 
solidifies around the ruptured area to prevent blood loss. A subordinate quantity of platelets 
can result in excessive bleeding. However, high platelet numbers can progress into blood 
clots, which may potentially be dangerous because they produce a condition known as 
thrombosis. Thrombosis precedes harmful conditions such as stroke, myocardial infarction, 
pulmonary embolism, and other conditions associated with the disruption of circulatory blood 
flow.  
Depending on the severity of the condition, there are different treatments available for 
thrombosis.  Some patients may require surgery for an illness caused by thrombosis.  In other 
instances, there are thrombolytic or fibrinolytic drugs that can be used as medicinal therapy to 
dissolve blood clots. Thrombolytic drugs disintegrate blood clots by converting plasminogen 
into plasmin. The plasmin, a serine protease, actually does the blood clot dissolving. The most 
important thrombolytic drug categories include tissue plasminogen activator and 
streptokinase (Klabunde 2005). While there are two significant families of thrombolytic 
medications that can be utilized in thrombolytic therapy, alteplase, a recombinant tissue 
plasminogen activator, is the preferred medication for treatment of acute ischemic stroke, 
myocardial infarction with ST elevation, and, in some rare cases, pulmonary embolism. 
DISCUSSION: 
THROMBOLYTIC THERAPY FOR STROKE 
For approximately a decade, stroke has been the third leading cause of death in the 
United States following cardiac diseases and cancer. Roughly 137,000 Americans die from 
stroke every year (Center for Disease Control 2009). Since stroke can cause brain cell damage 
or cell death, patients often exhibit sudden numbness or paralysis of the face, legs, or arms. 
Thus, stroke is the primary cause of permanent disabilities. There are two general 
classifications of stroke: ischemic strokes and hemorrhagic strokes. 
ISCHEMIC STROKES 
 Almost 90% of strokes are ischemic strokes, caused by decreased blood flow to the 
brain (Swanson 1998b). Whenever normal blood flow to the brain is interrupted, the neurons 
begin to die within minutes. Since brain cells require oxygen for survival, and they acquire 
oxygen from red blood cells, they begin to decline in function (see figure 1).  There are two 
subcategories of ischemic strokes: thrombotic and embolic. A thrombotic stroke is caused by 
the formation of a blockage, thrombus, in one of the arteries supplying the brain with blood. A 
thrombus forms from arteriosclerosis, which is created by an accumulation of fatty deposits.  
An embolic stroke occurs when the body carries a blood clot from an alternate origination to a 
blood vessel in the brain. For example, atrial fibrillation in one of the two upper chambers in 
the heart can proceed to the formation of a blood clot that will travel elsewhere in the body. 
Thrombolytic drugs are utilized in ischemic strokes to bust open the thrombus or embolus. In 
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the 1980s, the first drug developed for the treatment of stroke was streptokinase, but this 
medication was abandoned after it caused unacceptable incidence of cerebral hemorrhage 
(Saver and Lutsep 1995). Alteplase was developed, and research found it to be a safer and 
more efficient choice for thrombolytic therapy in ischemic stroke patients. An alternate study 
showed the efficacy of alteplase administered to acute ischemic stroke patients up to four 
hours after the onset of symptoms. 
 
Patients were admitted or excluded from the alteplase clinical trial based on various 
elements. Some of the inclusion criteria for the acute ischemic stroke trial were the ability to 
have the study drug administered between 3 and 4.5 hours after the onset of stroke symptoms 
and the presence of stroke symptoms for at least 30 minutes with no significant improvement. 
Some rejection criteria were  intracranial hemorrhage, seizures at the onset of stroke, and 
serious head injury within the previous three months. For a complete list of selective and 
dismissive criteria see table 1(Hacke et al. 2008). 
A total of 821 patients enrolled in the trial and were randomly assigned to either the 
alteplase group or a placebo group.  The alteplase group had 418 patients, and the placebo 
group had 403 patients. Approximately 82 patients were administered the drug or a placebo 
between 3 and 3.5 hours, 384 patients obtained it between 3.5 and 4 hours, and 322 received it 
between 4 and 4.5 hours. Of the remaining patients, treatment time for 12 patients from the 
alteplase group and 15 patients from the placebo group were not obtainable. Additionally, one 
patient from the alteplase group and five patients from the placebo group were administered 
treatment after 4.5 hours. The trial result was a ratio of 41.6% to 36.7% in favor of the 
alteplase group.   Although the results indicated more symptomatic  intracranial hemorrhage 
Figure 1: Ischemic Stroke: The illustration shows how an ischemic stroke can occur in the brain. If a 
blood clot breaks away from plaque buildup in a carotid (neck) artery, it can travel to and lodge in an 
artery in the brain. The clot can block blood flow to part of the brain, causing brain tissue death.         
 Source: http://www.nhlbi.nih.gov/health/dci/images/stroke_ischemic.jpg 
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in the alteplase group than in the placebo group, the overall outcome of the trial showed a 
more favorable result for the alteplase group in the 4.5 hours range.  This indicates that 
supplying alteplase intravenously can clinically better the condition of ischemic stroke patients 
up until 4.5 hours following the incipience of symptoms (Hacke et al. 2008).  
HEMORRHAGIC STROKES 
 Hemorrhagic strokes take place following a rupture or leak from a blood vessel in the 
brain (Figure 2). There are two subdivisions of hemorrhagic strokes: intracerebral 
hemorrhage and subarachnoid hemorrhage (Swanson 1998a). In an intracerebral 
hemorrhagic stroke, a blood vessel bursts causing blood seepage into brain tissue. The sudden 
increase in pressure within the brain can cause cellular damage. Furthermore, the brain cells 
beyond the ruptured blood vessel are damaged due to the interruption of blood flow and 
oxygen delivery. A subarachnoid hemorrhagic stroke is caused by leakage from a blood vessel 
into the space between the surface of the skull and the brain. Hemorrhagic strokes are not 
treated with thrombolytic therapy because of the major risk of further hemorrhaging. 
Source: Hacke et al. 2008 
Table 1: Major exclusion and inclusion criteria. 
 Alteplase: The Clot-Buster 85 
 
 
THROMBOLYTIC THERAPY FOR MYOCARDIAL INFARCTION 
 Major heart disease is the leading cause of death in the United States.  According to 
the CDC, nearly 48% of all deaths reported in 2010 were cardiac related. Heart attack, also 
known as acute myocardial infarction, happens when there is an interruption of the blood 
 
Figure 2: Hemorrhagic Stroke: The illustration shows how a hemorrhagic stroke can 
occur in the brain. An aneurysm in a cerebral artery breaks open, which causes bleeding 
in the brain. The pressure of the blood causes brain tissue death. 
 Source: http://www.nhlbi.nih.gov/health/dci/images/stroke_hemorrhagic.jpg 
Figure 3: Heart with Muscle Damage and a Blocked Artery: Figure A shows a heart with dead heart 
muscle caused by a heart attack. Figure B is a cross-section of a coronary artery with plaque buildup and a 
blood clot. 
Source: http://www.nhlbi.nih.gov/health/dci/images/heart_coronary_artery.gif 
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flow to the heart, causing the cardiac muscles to die (Pub Med Health 2010a). Many heart 
attacks are caused by blood clots forming an obstruction in one of the coronary arteries, 
which carries blood and oxygen to the heart tissues. The blockage disrupts the oxygen flow to 
heart tissues, causing heart muscle cell death (Figure 3). Atherosclerosis, a principle cause of 
blockages, is the accretion of plaque that adheres to the coronary artery walls and forms an 
occlusion. The plaque may tear, and blood platelets may fasten to it forming a thrombus (Pub 
Med Health 2010a). A myocardial infarction (MI) can be classified as a non-ST elevation MI 
or an ST elevation MI based on electrocardiogram changes (Cleveland Clinic 2009). 
MYOCARDIAL INFARCTION WITH NON-ST SEGMENT ELEVATION 
A non-ST elevation MI does not exhibit changes on an electrocardiogram. 
Additionally, the extent of damage is minimal since the artery is only partially obstructed 
(Cleveland Clinic 2009). According to the American Heart Association, there is a close 
correlation between non-ST elevation MI and unstable angina. Unstable angina is a condition 
caused by a diminished supply of blood flow and oxygen to the heart; as research indicates, it 
can be an introduction to a heart attack (Pub Med Health 2010b). Non-ST elevation MI and 
unstable angina are treated by anti-platelet agents, anti-thrombin agents, or anti-ischemic 
agents (Jevon et al. 2008). Although the treatments for non-ST elevation myocardial 
infarction and unstable angina are similar, there is a different course of action taken for a 
myocardial infarction with ST elevation. 
MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION 
An ST-elevation MI is caused by the prolonged obstruction of blood supply that 
affects a large portion of the heart. Thus, ST segment changes on an electrocardiogram are 
clearly visible and are easily detected (Cleveland Clinic 2009). If ST-elevation MI is detected 
early enough, thrombolytic treatment can be an essential part in its treatment as thrombolytics 
restore blood flow, thus decreasing casualties. Thrombolytic treatment is the preferred 
treatment for ST segment myocardial infarction, because it is the most effective at achieving 
reperfusion. Thrombolytic treatment can effectively restore blood flow when administered 
within 12 hours of symptom onset, but maximum benefit is obtained when administered 
promptly (Hilleman et al. 2007).  
The Global Utilization of Streptokinase and Tissue Plasminogen Activator for 
Occluded Coronary Arteries, known as the Gusto-I trial, was conducted to compare the 
efficacy of streptokinase and alteplase in ST segment myocardial infarction. Additionally, the 
study determined whether earlier and sustained reperfusion with alteplase improves the 
survival rate in people with acute myocardial infarction. A total of 41,021 patients within six 
hours of the onset of acute myocardial infarction with ST segmentation were randomly 
assigned to one of four thrombolytic treatments: streptokinase, streptokinase with intravenous 
heparin, accelerated tissue plasminogen activator, or tissue plasminogen activator with 
intravenous heparin. The primary follow-up and end point of the trial was 30 days (Hacke et 
al. 2008).  
After the 30 days, the results indicated that patients receiving accelerated tissue 
plasminogen activator had a more significant reduction in mortality during the 30-day period 
than those administered streptokinase and any other combined strategies. There was, 
however, an increase of hemorrhagic stroke episodes in accelerated tissue plasminogen 
activator patients above the others.  Still, the overall endpoint of death or permanent disability 
was lower in patients administered accelerated tissue plasminogen activator than in patients 
administered any other combination. A Gusto-III trial was soon established to determine if 
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reteplase, a newer recombinant tissue plasminogen activator, was better than alteplase. More 
than 15,000 patients, all within six hours of the onset of symptoms, entered the trial. The 30-
day mortality rate for reteplase did not exhibit any additional survival benefits in acute 
myocardial infarction (Hacke et al. 2008).     
THROMBOLYTIC THERAPY FOR PULMONARY EMBOLISM 
A pulmonary embolism is an occluded artery that disrupts the blood flow to the lungs. 
Deep vein thrombosis, the most common cause of pulmonary embolism, occurs when an 
embolus that originated in a deep thigh vein travels up to the lungs and blocks the blood flow 
(Fischbein 1981). Pulmonary embolism is an extremely dangerous condition, since it may 
cause damage to lung tissue due to a diminished oxygen supply. Additionally, it can damage 
other organs due to a lack of oxygen and, in some severe cases, may even cause death. 
Pulmonary embolism affects men as well as women. If the pulmonary embolism is caused by 
deep vein thrombosis, patients may exhibit symptoms such as 
swelling of the leg, pain or tenderness in the leg, or a 
discoloration of the skin on the affected area. Pulmonary 
embolism is responsible for 10% of all deaths, and an initial 
diagnosis is not straightforward.  In fact, in 70% of all 
pulmonary embolism patients, it was not clinically suspected 
but confirmed after an autopsy (Davidson 1999) (Figure 4). 
A majority of patients with pulmonary embolism are 
treated with anticoagulation medication. Anticoagulation 
therapy is beneficial in the treatment of pulmonary embolism, 
because it provides prophylaxis against further 
thromboembolic events while the body's own fibrinolytic 
system gradually lyses the embolus. Since dissolving the clot 
is the treatment for pulmonary embolism, many have 
wondered if thrombolytic therapy would be even more 
efficient as thrombolytic drugs dissolve clots more rapidly 
than endogeneous fibrinolytic activity can. There was a study 
comparing the efficacy of recombinant tissue plasminogen 
activator and anticoagulants in pulmonary embolism. As part 
of the study, 790 stable patients with pulmonary embolism 
were randomly assigned to either the heparin (anticoagulant) 
group or the alteplase (recombinant tPA) group. While 169 
patients received recombinant tissue plasminogen activator, 
550 patients received heparin alone. The overall 30-day 
mortality rate for patients administered tissue plasminogen 
activator compared to those receiving heparin was 4.7% to 
11.1% respectively. Additionally, during the in-hospital 
phase, recurrence of pulmonary embolism was more frequent 
in patients taking heparin. In fact, the ratio of recurrence was 7.7% to 18.7% in favor of 
alteplase (Arcasoy and Kreit 1999). 
SYNTHESIS OF THROMBOLYTIC DRUGS 
ALTEPLASE 
Alteplase is beneficial in thrombolytic treatment because it is easily synthesized using 
recombinant DNA technology. The composition of alteplase consists of a purified 
Figure 4: Deep vein thrombosis 
can cause pulmonary embolism  
Source: Fischbein 1981 
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glycoprotein consisting of 527 amino acids.  It is synthesized using a complementary DNA 
from a human melanoma cell line. Alteplase is manufactured by secretion of an alteplase 
enzyme into a culture medium. After secretion of the enzyme, the antibiotic gentamicin is 
added to the culture causing fermentation. Gentamicin, however, is not present in the 
recombinant tissue plasminogen product. The product also undergoes lyophilization, which is 
the process of rapidly freezing and dehydrating in a vacuum (Genetech 2005). 
STREPTOKINASE  
  On the other hand, streptokinase is a drug easily synthesized from a "-hemolytic 
streptococcus culture. However, there is a major drawback to using streptokinase. Most 
people have had a streptococcal infection at some point in their lives, so they are likely to have 
built up antibodies against streptococcal bacteria. Streptokinase is produced from 
streptococcal bacteria, so the circulating antibodies are likely to neutralize its effect on the 
clots (Finkel et al. 2009). Furthermore, once administered to a patient, streptokinase cannot 
be used again for some time due to its antigenic property.  Thus, the antigenic property of 
streptokinase is one of the most significant detriments to the drug.   
MECHANISM OF ACTION 
ALTEPLASE 
Alteplase has a mechanism of action that makes it fibrin specific and thus favorable for 
thrombolytic therapy (Figure 5).  First, alteplase attaches to fibrin on the surface of a clot and 
initiates fibrin bound plasminogen. Then plasmin is cleaved from the plasminogen associated 
with the fibrin, fibrin molecules are broken apart by the plasmin, and the clot dissolves. 
Although alteplase has a low attraction for plasminogen in the plasma, it activates 
plasminogen attached to fibrin in a blood clot (Klabunde 2005). Alteplase’s fibrin selectivity is 
what makes it therapeutically useful. Thus, administering alteplase in low doses lyses only the 
wanted clot without degrading other proteins. 
 
STREPTOKINASE 
Streptokinase is a protein cultured from the broth of streptococci bacteria. Since 
streptokinase is not a protease, it contains no enzymatic activity and has a different 
mechanism of action than alteplase. Streptokinase forms an active complex with the 
plasminogen (Figure 6).  The active complex activates and releases the plasmin to dissolve the 
clots (Klabunde 2005). However, streptokinase is not fibrin specific and, therefore, its 
Figure 5: (1) Recombinant t-PA (alteplase) binds to fibrin in thrombus 
(2) converts entrapped plasminogen to plasmin (3) that initiates local 
fibrinolysis.  
Source: http://www.cathflo.com/images/moa.gif 
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associated plasmin lyses circulating and non-circulating plasminogen. Streptokinase decays 




PHARMACOKINETICS OF THE THROMBOLYTIC DRUGS 
Pharmacokinetics is the pharmacological research of drug movement within the body. 
Moreover, it studies the mechanism of absorption, span of drug impact, and chemical 
modifications the body experiences. On certain occasions, a drug will be administered 
intravenously to ensure that the distribution of medication is instantaneous and efficacious. 
The half-life of a medication is the moment it takes a medication to decrease to half its original 
potency. Consequently, half-life forecasts the length of time it will take for a drug to leave the 
blood plasma. Therefore, if a drug contains a relatively brief half-life, the body disposes and 
eliminates that drug quickly. In contrast, when a medication has a prolonged half-life it lingers 
in the blood plasma for an extended period of time.  Thus, half-life is a good indicator for drug 
dosage, because it measures the length of time it takes for the body to dispose of a medication. 
While sometimes a short half-life is beneficial for patients, other times a long half-life is 
advantageous for a patient. 
HALF-LIFE OF THROMBOLYTIC DRUGS     
Alteplase has an extremely brief half-life of approximately five minutes. There is an 
advantage and a disadvantage to the short half-life in alteplase. An advantage is that alteplase 
is a powerful clot busting medication that lyses only a specific clot and is eliminated from the 
body in a very brief time. A disadvantage of alteplase’s short half-life is the increased 
possibility of reocclusion (Greer 2007). In contrast, streptokinase has a much longer half-life 
than that of alteplase. However, the longer half-life of streptokinase also has disadvantages, 
since streptokinase has antigenic properties and poses the risk of other allergic reactions. 
Additionally, it is usually unsafe to administer streptokinase a second time within 6 months 
due to its highly antigenic property (Rivera-Bou and Brown 2010).  
CONCLUSION 
The Food and Drug Administration approved alteplase as a treatment for acute 
ischemic stroke on June 8, 1996. Astonishingly, to this very day, alteplase is the sole approved 
medication for patients suffering from ischemic stroke. Additionally, it has bumped stroke 
from the third leading cause of death to the fourth leading cause of death in the United States 
Figure 6: Streptokinase and its effect on the fibrinolytic system. 
Source: http://www.anzcp.org/CCP/Pharmacology/streptokinase_files/image002.gif 
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(Center for Disease Control 2010). The Gusto-I and Gusto-III trials indicate that alteplase is 
a more practical and powerful drug than streptokinase in patients suffering from myocardial 
infarction with ST segmentation. In fact, according to the American Heart Association, the 
ideal time to administer thrombolytic drugs is within 90 minutes after the heart attack. 
However, if administered up to 12 hours after the onset of symptoms, the chances of surviving 
and recovering are still enhanced (Health Guide 2010). 
Pulmonary embolism is not an easily detected condition, but deep vein thrombosis, an 
equally serious condition, is detectable.  The use of alteplase in acute massive pulmonary 
embolism has shown more efficient and steadfast results than that of anticoagulation therapy. 
Due to an extremely brief half-life, possibly resulting in reocclusion, alteplase has come under 
fire.  However, with the use of recombinant technology, more generations of alteplase are 
being synthesized and produced to enhance the already proficient drug.     
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